Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

The Oncologist
Ralph V BocciaPeter T Silberstein

Abstract

Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 mug) Q3W in patients with CIA. Eligible patients (> or =18 years) were anemic (hemoglobin <11g/dl), had a nonmyeloid malignancy, and were receiving multicycle chemotherapy. This analysis includes 1,493 patients who received at least one dose of darbepoetin alfa. The effect of baseline hemoglobin (<10 or > or =10 g/dl) on clinical outcomes was evaluated. Patients in the > or =10-g/dl stratum achieved the hemoglobin target range (11-13 g/dl)in less time than patients in the <10-g/dlstratum (3 weeks vs. 9 weeks). More patients in the > or =10-g/dl stratum achieved the hemoglobin target range (87% vs. 66%); however, similar proportions of patients in both strata maintained hemoglobin within the target range (73% vs. 71%). Fewer patients in t...Continue Reading

References

Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LittlewoodUNKNOWN Epoetin Alfa Study Group
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GabriloveL H Einhorn
Aug 22, 2002·Journal of the National Cancer Institute·Johan VansteenkisteUNKNOWN Aranesp 980297 Study Group
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Clinical Oncology. American Society of Hematology
Oct 3, 2002·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin alfa 990114 Study Group
Nov 13, 2002·Kidney International·Yves VanrenterghemUNKNOWN European/Australian NESP 970200 Study Group
Jul 25, 2003·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin Alfa 20000161 Study Group
Aug 7, 2003·The Lancet Oncology·Brian Leyland-Jones, UNKNOWN BEST Investigators and Study Group
Sep 6, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D KotasekUNKNOWN Aranesp 980291 Study Group
Sep 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BokemeyerP Soubeyran
Mar 29, 2005·Best Practice & Research. Clinical Haematology·John Glaspy
Apr 30, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G JusticeR G Amado
May 25, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John GlaspyUNKNOWN Darbepoetin Alfa 20010162 Study Group
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-JonesEls Vercammen

❮ Previous
Next ❯

Citations

Jun 2, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Vernon P MontoyaFrancois E Wilhelm
Jul 25, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Melike DegerSam Salek
Jun 13, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jerrold W HillPatricia K Corey-Lisle
Dec 7, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J M Jurado GarcíaE Alba Conejo
Aug 1, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jaime Sanz Ortiz
Mar 25, 2008·Therapeutics and Clinical Risk Management·Alberto GrossiSimone Santini
Jul 16, 2009·Current Medical Research and Opinion·Enrique HernandezUNKNOWN ARANESP 20030232 Study Group
Sep 9, 2008·Critical Reviews in Oncology/hematology·Fabio PuglisiPatrizia Beccaglia
Mar 14, 2008·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Stacy S ShordSandra Cuellar
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert PirkerJohan F Vansteenkiste
Dec 7, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Raymond J Muller, David Baribeault
Dec 31, 2008·Biological Research for Nursing·Sadeeka Al-Majid, D Patricia Gray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.